Tracey McCulloch
Novartis (Switzerland) · 21 works · 1,410 citations · h-index 8
Top works
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
- Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
- Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers
- ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.
- PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
- Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study
- Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors
- Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
- ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
- P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4)
- CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis
- ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results
- POSTER: CML-1050: ASC4FIRST Week 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- ASC4FIRST wk 144 analysis: Efficacy and safety and tolerability with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed (ND) chronic myeloid leukemia in chronic phase (CML-CP).
- POSTER: CML-754 Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis
- ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results
- Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia
- Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
- CML-387 ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results